Amikacin in Medical Technology
Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be
Presented at American Thoracic Society International Conference
SAN FRANCISCO--(BUSINESS WIRE)--May 9, 2007 - Results of a Phase 2a
clinical trial evaluating the potential of NKTR-061 (inhaled
amikacin) to treat hospital acquired gram-negative bacterial
pneumonia will be presented at the American Thoracic Society (ATS)
International Conference, May 18 - 23, 200...
Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
...d to Transave Inc., for the continued development of ARIKACE(TM) (liposomal amikacin
for inhalation), an antibiotic that aims to treat Pseudomonas lung infect...osomes. This advanced pulmonary liposome technology prolongs the release of amikacin
in the lungs while minimizing systemic exposure. The treatment uses biocomp...
Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
...atients were at least 4-fold lower than those obtained for tobramycin, amikacin
and aztreonam. -- Spectrum: MIC90s for MP-376 against clinical isolates ...sed less than two fold under anaerobic conditions, whereas tobramycin, amikacin
and aztreonam treated isolates increased 4-7 fold under anaerobic cond...
Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
investigational drug, Arikace(TM) (liposomal amikacin
for inhalation). The
compound is being developed f... a Phase III trial. "This
formulation of liposomal amikacin
was specifically designed for sustained
results support the potential value of delivering amikacin
Transave's next-generation liposomal techn...
Amikacin Inhale Shows Promising Results in Phase II Study
... without reaching high
Inhale is a unique drug-device combination, being ...iquid formulation of the aminoglycoside antibiotic amikacin
Nektar Therapeutics' proprietary Liquid Pulmonary Technology (LPT(TM)),
designed to deliver amikacin
deep into the infected lungs.
The device can be ...
Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
...n pneumonic portions of lung"
Poster #517: "Evidence of High amikacin
Lung Deposition in Mechanically Ventilated Patients (MVP) with Pneum... Subjects (HS) dosed using NKTR-061"
Poster #518: "High in vivo amikacin
lung deposition after NKTR-061 dosing correlates with in vitro aeros...
Nektar Threraputics Announces Phase 2a Clinical Results Regarding
the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative
Hospital-Acquired Pneumonia Presented at the Annual American
Thoracic Society International Conference
... www.nektar.com: -0-
-- Poster Board #710: amikacin
Aerosol Achieves High Epithelial
Lining F... alveoli.
Objective: Evaluate aerosol amikacin
(AMK) penetration into
the epithelial lun...
-- Poster Board #718
Reduces IV Antibiotic Use in Intubated
Amikacin in Biological News
Clues to gene expression in cystic fibrosis will guide research
...al drug option, as it may cause serious side effects for some patients, including ear and kidney damage. The authors suggest that other drugs, such as amikacin
or PTC124, with a comparable mode of action and fewer side effects, may have treatment potential. The in vitro method used to predict the trial’s out...
Amikacin in Biological Technology
Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
SAN CARLOS, Calif., Oct. 21 /PRNewswire-FirstCall/ -- (11:00 PM PT,
Oct. 20) -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that
Novartis AG has agreed to acquire from Nektar specific pulmonary delivery
assets, technology, and intellectual property for $115 million in cash.
Transave Enters Into Cooperative Research Agreement With NIH To Study ARIKACE(TM) In Nontuberculous Mycobacteria
...of the National Institutes of Health (NIH), to study ARIKACE(TM) (liposomal amikacin
for inhalation) in patients with nontuberculous mycobacteria (NTM) lung inf...somes. This advanced pulmonary liposome technology prolongs the release of amikacin
in the lungs while minimizing systemic exposure. The treatment uses biocom...
Transave, Inc. Secures $12.5 Million in New Financing
...d positive Phase II data on Arikace(TM)
for inhalation) from a randomized, placebo-control...h and quality of life."
About Arikace (liposomal amikacin
Arikace is a form of the antibiotic amikacin
that is enclosed in
nanocapsules of lipid called l...
Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing
...our lead clinical compound, ARIKACE(TM)
for inhalation). We are on track to have Arikace P...rtible preferred
About ARIKACE (liposomal amikacin
ARIKACE is a form of the antibiotic amikacin
that is enclosed in
nanocapsules of lipid called l...
Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients
... release and
in vivo activity of inhaled liposomal amikacin
in chronic Pseudomanas
aeruginosa lung infections,...Pseudomonas in the biofilm that trigger
release of amikacin
from the liposomes. These factors are expected to ...arget for
antibiotics and the triggered release of amikacin
resulted in what was
essentially Pseudomonas suici...
Amikacin in Biological Definition
There are many way to classify antibiotics.
One such classification is by chemical structure: